Please login to the form below

Not currently logged in


This page shows the latest SMC news and features for those working in and with pharma, biotech and healthcare.

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).

Latest news

More from news
Approximately 15 fully matching, plus 76 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year.

  • The Orkambi row explained The Orkambi row explained

    December 2018: Scottish Government agrees a deal with Vertex pending submission of Orkambi and Symkevi to Scottish Medicines Consortium (SMC), with interim access possible through the PACS Tier 2 system.

  • The Orkambi blame game The Orkambi blame game

    Leiden also claimed the breakthrough in Scotland came when NICE’s equivalent, the SMC, agreed to ‘flex’ its methodology – something which he and other industry leaders said is vital if NICE

  • Patient involvement in health technology assessment Patient involvement in health technology assessment

    We have developed a Public Involvement Network (PIN) that formalises relationships with each submitting patient group through a registration process to become an SMC Patient Group Partner. ... SMC as a respected partner in developing and shaping all

  • The reality of real-world evidence The reality of real-world evidence

    Zaltrap re-submission to the Scottish Medicines Consortium (SMC) included RWE (pooled data from two open-label, single-arm studies) to demonstrate prolonged safety and QoL benefit.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • YorkTown

    decision makers associated with pharmaceutical and medical device/diagnostics market access and HEOR; Developing and writing single technology appraisals (STA) (pharmaceutical and medical device) for regulatory institutions (NICE, EMA, SMC and

  • The Holistic Approach to Market Access

    and to provide local prescribing audit data for inclusion into NICE and SMC technical appraisals the gaining of which is a key element in gaining regional prescribing uptake.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....